Abstract
AMCA is the most effective of the antifibri-nolytic substances suitable for clinical use. After oral or intravenous administration, AMCA is largely excreted unchanged in the kidneys and inhibits the fibrinolytic activity of the urine. This has often the consequence that haematuria is arrested. The preparation was given to 172 patients with different urinary tract diseases having in common haematuria. We found side effects to be mild and uncommon. AMCA is a valuable adjunct in the treatment of urinary tract bleeding.